---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009162"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:42:41.371295+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics reports FY2022 net loss $63.3M; cash $98.5M; RT-102 Phase 2 in H2 2023

## Summary
- Net loss $63.3M for 2022, vs $53.1M in 2021; cash $98.5M, sufficient to mid-2024.
- Phase 1 data for RT-102 (osteoporosis) positive; FDA agrees 505(b)(2) pathway; Phase 2 planned H2 2023.
- Partnership with Celltrion for RT-111 (ustekinumab biosimilar); exclusive license with right of first negotiation.
- Expects to start three Phase 1 studies in 2023 for RT-105, RT-110, RT-111.

## SEC filing metadata
- accession: 0000950170-23-009162
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/0000950170-23-009162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/rani-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009162
- JSON: https://secwatch.observer/filing/0000950170-23-009162.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009162.txt

## Key facts
- Earnings Releases
  Rani Therapeutics Holdings, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss for the three and twelve months ended December 31, 2022 was $17.3 million and $63.3 million, respectively.
  - Period: the fourth quarter and year ended December 31, 2022
  - Net income: Net loss for the three and twelve months ended December 31, 2022 was $17.3 million and $63.3 million, respectively
  - Result: reported results
  source text: On March 22, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023009162/0000950170-23-009162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.